Search

Displaying results 5871 - 5880 of 7895 in total
  1. Drug

    MCC

    go.drugbank.com/drugs/DB05282
    Investigational

    The product is a sterile biological composition in a sub-micron suspension. It is produced at the Bioniche manufacturing facility in Pointe-Claire, Quebec. … Mycobacterial Cell Wall-DNA Complex (MCC) is formulated from Mycobacterium phlei, a non-pathogenic strain of mycobacteria.

  2. Drug

    QR-333

    go.drugbank.com/drugs/DB05533
    Investigational

    QR-333 has been investigated as a treatment for diabetic peripheral neuropathy. … QR-333 is a concentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder

  3. Drug

    Faropenem medoxomil

    go.drugbank.com/drugs/DB05659
    Investigational

    Faropenem medoxomil is an ester prodrug derivative of the beta-lactam antibiotic [faropenem]. … Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc.

  4. Drug

    1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline

    go.drugbank.com/drugs/DB08555
    Experimental

    These are aromatic polycyclic compounds containing an isoquinoline moiety, which consists of a benzene ring fused to a pyridine ring and forming benzo[c]pyridine. … 1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline is a solid. This compound belongs to the isoquinolines and derivatives.

  5. Drug

    J147

    go.drugbank.com/drugs/DB13957
    Experimental

    [A31606,A31607,A31608] It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging … J147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  6. Drug

    Taspoglutide

    go.drugbank.com/drugs/DB14027
    Investigational

    As of May 2013 no new trials had been registered. … Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche.

  7. Drug

    OAV201

    go.drugbank.com/drugs/DB17842
    Experimental

    OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter

  8. Drug

    AZD7442

    go.drugbank.com/drugs/DB15787
    Investigational

    [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591] … AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19.

  9. Drug

    CIGB 2020 Vaccine

    go.drugbank.com/drugs/DB15808
    Experimental

    As of July, 2020, a Randomized control clinical trial (RPCEC00000306) is underway to evaluate prophylaxis potential in suspected contacts of Covid-19 patients. … CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered.

  10. Drug

    Adlinacogene civaparvovec

    go.drugbank.com/drugs/DB16788
    Investigational

    Adlinacogene civaparvovec is an investigational _in vivo_ genome editing therapeutic product. … It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX.